ago2  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Name:
    Argonaute 2 cDNA ORF Clone in Cloning Vector Human
    Description:
    Full length Clone DNA of Human eukaryotic translation initiation factor 2C 2
    Catalog Number:
    HG11079-M
    Price:
    75.0
    Category:
    cDNA Clone
    Size:
    1Unit
    Product Aliases:
    Argonaute 2 cDNA ORF Clone Human, EIF2C2 cDNA ORF Clone Human, Q10 cDNA ORF Clone Human
    Molecule Name:
    AGO2,KIAA4215,Argonaute-2,
    Buy from Supplier


    Structured Review

    Sino Biological ago2
    <t>Ago2</t> and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Full length Clone DNA of Human eukaryotic translation initiation factor 2C 2
    https://www.bioz.com/result/ago2/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ago2 - by Bioz Stars, 2021-07
    97/100 stars

    Images

    1) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    2) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    3) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    4) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    5) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    6) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    7) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    8) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    9) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    10) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    11) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    12) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    13) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    14) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    15) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    16) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    17) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    18) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    19) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    20) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    21) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    22) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    23) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    24) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    25) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    26) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    27) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    28) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    29) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    30) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    31) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    32) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    33) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    34) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    35) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    36) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    37) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    38) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    39) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    40) Product Images from "Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis"

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    Journal: BioMed Research International

    doi: 10.1155/2020/2370253

    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P
    Figure Legend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Techniques Used: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P
    Figure Legend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Techniques Used: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P
    Figure Legend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Techniques Used: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).
    Figure Legend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Techniques Used: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control

    Related Articles

    other:

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis
    Article Snippet: It was verified from the results that septic plasma could significantly increase the intracellular Ago2 and miR-21a-3p contents, while the reduction of Ago2 in septic plasma could suppress this phenomenon.

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis
    Article Snippet: Argonaute-2 (Ago2) is a highly conserved member of the Argonaute family in species and it has been revealed that small RNA-guided gene silencing can be regulated by Ago2 in humans [ ].

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis
    Article Snippet: There must be receptors expressed on the cell membrane of TECs which can mediate internalization so that miR-21a-3p could be internalized associated with Ago2.

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis
    Article Snippet: Hence, to verify whether miR-21-3p could be internalized via Nrp-1, it was also important to find out if miR-21a-3p could bind to Nrp-1 in the presence or absence of Ago2.

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis
    Article Snippet: For the Ago2 and miR-21a-3p costimulation, equimolar Ago2 and miR-21a-3p were premixed for 1 hour to form the Ago2/miR-21a-3p mimics complex before use.

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis
    Article Snippet: It can be concluded from the results that Ago2 was the key factor in the rise of miR-21a-3p in TECs stimulated by septic plasma and that conclusion further supported our hypothesis that Ago2 may mediate the internalization of exogenous miR-21a-3p into TECs during sepsis.

    Stable Transfection:

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis
    Article Snippet: Ago2 binds and stabilizes the miRs in the plasma. .. Previous studies have verified that microRNAs can only stably exist in circulation when forming complexes with Ago2 or HDL or are contained in exosomes [ , ]. .. In our present study, it was revealed that the Ago2 content in both plasma and TECs rose remarkably and Ago2 binding miR-21a-3p increased significantly during sepsis.

    Binding Assay:

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis
    Article Snippet: .. Both Ago2 and miR-21a-3p Could Bind to TEC-Derived Nrp-1 DirectlyTo further verify whether TEC-derived Nrp-1 could mediate the internalization of Ago2 as well as the Ago2 binding miR-21a-3p in TECs, it is crucial to find out whether TEC-derived Nrp-1 could interact with Ago2 and miR-21a-3p directly. .. Firstly, immunoprecipitation was carried out with lysates from different groups of TECs, the results suggested that TEC-derived Nrp-1 did bind to Ago2 directly ( ).

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Sino Biological ago2
    <t>Ago2</t> and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P
    Ago2, supplied by Sino Biological, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ago2/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ago2 - by Bioz Stars, 2021-07
    97/100 stars
      Buy from Supplier

    Image Search Results


    Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Journal: BioMed Research International

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    doi: 10.1155/2020/2370253

    Figure Lengend Snippet: Ago2 and miR-21a-3p levels in TECs with or without Nrp-1 knockdown treated with septic plasma. (a) Representative Western Blot results of cytoplasm Ago2 of TECs with different treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs with different treatments ( ∗ P

    Article Snippet: Hence, to verify whether miR-21-3p could be internalized via Nrp-1, it was also important to find out if miR-21a-3p could bind to Nrp-1 in the presence or absence of Ago2.

    Techniques: Western Blot, Quantitative RT-PCR

    Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Journal: BioMed Research International

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    doi: 10.1155/2020/2370253

    Figure Lengend Snippet: Exogenous Ago2 in TECs with different treatments. (a) Representative fluorescent results of cytoplasm Ago2 of TECs with different treatments. (b) Representative flow cytometry results of Ago2 in TECs with different treatments. (c) Quantitative analysis of flow cytometry results of Ago2 in TECs with different treatments. (d) Representative Western Blot results of cytoplasm Ago2 in TECs with different treatments. (e) Representative Western Blot results of cytoplasm His residue at 99 Kd in TECs with different treatments. (f) Representative results of immunoprecipitation of Ago2 binding His residue of TECs in the control and exogenous Ago2-treated groups. (g) Quantitative analysis of RT-PCR results of intracellular miR-21a-3p of TECs with different treatments ( ∗ P

    Article Snippet: Hence, to verify whether miR-21-3p could be internalized via Nrp-1, it was also important to find out if miR-21a-3p could bind to Nrp-1 in the presence or absence of Ago2.

    Techniques: Flow Cytometry, Western Blot, Immunoprecipitation, Binding Assay, Quantitative RT-PCR

    Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Journal: BioMed Research International

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    doi: 10.1155/2020/2370253

    Figure Lengend Snippet: Ago2 and miR-21a-3p levels in TECs stimulated with differently treated plasma. (a) Quantitative analysis of the results from ELIA for Ago2 and RT-PCR for miR-21a-3p of plasma with or without treatments. (b) Quantitative analysis of RT-PCR results of miR-21a-3p of TECs treated with different plasma. (c) Representative results of flow cytometry for Ago2 in TECs treated with different plasma. (d) Quantitative analysis of the results of flow cytometry for Ago2 in TECs treated with different plasma. (e) Representative Western Blot results of Ago2 in TECs treated with different plasma ( ∗ P

    Article Snippet: Hence, to verify whether miR-21-3p could be internalized via Nrp-1, it was also important to find out if miR-21a-3p could bind to Nrp-1 in the presence or absence of Ago2.

    Techniques: Reverse Transcription Polymerase Chain Reaction, Quantitative RT-PCR, Flow Cytometry, Western Blot

    miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Journal: BioMed Research International

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    doi: 10.1155/2020/2370253

    Figure Lengend Snippet: miR-21a-3p and Ago2 levels of both TECs and plasma during sepsis. (a) Quantitative analysis of RT-PCR results of miR-21a-3p of either plasma or TECs at different time points. (b) Quantitative analysis of ELISA for Ago2 concentrations of plasma at different groups. (c) Representative RIP results of Ago2 binding miR-21a-3p in plasma of different groups. (d) Representative Western Blot results of Ago2 in TECs of the control group and CLP groups at different time points ( ∗ P

    Article Snippet: Hence, to verify whether miR-21-3p could be internalized via Nrp-1, it was also important to find out if miR-21a-3p could bind to Nrp-1 in the presence or absence of Ago2.

    Techniques: Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Binding Assay, Western Blot

    Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Journal: BioMed Research International

    Article Title: Nrp-1 Mediated Plasmatic Ago2 Binding miR-21a-3p Internalization: A Novel Mechanism for miR-21a-3p Accumulation in Renal Tubular Epithelial Cells during Sepsis

    doi: 10.1155/2020/2370253

    Figure Lengend Snippet: Interaction of Nrp-1 with either Ago2 or miR-21a-3p. (a) Representative results of immunoprecipitation of the cell lysates of TECs with different treatments; the lysates were immunoprecipitated with Ago2 antibody and probed with Ago2 and Nrp-1 antibodies after electrophoresis. (b) Representative results of RNA pull-down assay for lysates of TECs treated with biotin-miR-21a-3p single strain mimics. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting. (c) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated and Nrp-1 was probed with immunoblotting. (d) Representative results of RNA pull-down assay for biotin-miR-21a-3p/Ago2/Nrp-1 mixture. Biotin-miR-21a-3p was precipitated; Ago2 and Nrp-1 were probed with immunoblotting (Ctrl: control; SiNrp-1: Nrp-1 siRNA transfection; SiRNA NC: siRNA negative control transfection; NC: miR-21a-3p mimic negative control; Mimic: miR-21a-3p mimics).

    Article Snippet: Hence, to verify whether miR-21-3p could be internalized via Nrp-1, it was also important to find out if miR-21a-3p could bind to Nrp-1 in the presence or absence of Ago2.

    Techniques: Immunoprecipitation, Electrophoresis, Pull Down Assay, Transfection, Negative Control